Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	33.00B
Revenue (ttm)	12.95B
Net Income (ttm)	2.34B
Shares Out	n/a
EPS (ttm)	2.61
PE Ratio	14.09
Forward PE	13.55
Dividend	1.20 (3.84%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,183,139
Average Volume	982,089
Open	30.60
Previous Close	30.72
Day's Range	30.56 - 31.66
52-Week Range	24.85 - 41.85
Beta	0.23
RSI	34.42
Earnings Date	Oct 24, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY